G1 Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Operational Highlights

Genetics Investing

G1 Therapeutics (Nasdaq:GTHX), a clinical-stage oncology company, today reported financial results for the fourth quarter and full year ended December 31, 2017, and provided an update on its corporate activities and product pipeline. As quoted in the press release: “G1 has made significant progress over the last five months, filing and opening two INDs, expanding …

As quoted in the press release:

“G1 has made significant progress over the last five months, filing and opening two INDs, expanding our clinical collaborations with the signing of the Tagrisso deal with AstraZeneca and beating the estimate for completion of patient enrollment by two quarters for our Phase 2 trial of trilaciclib in combination with Tecentriq,” said Mark Velleca, M.D., Ph.D., Chief Executive Officer of G1 Therapeutics. “Our recent accomplishments and ongoing clinical programs will drive several significant data readouts throughout 2018, beginning next month with the announcement of topline myelopreservation data from the Phase 2a trial of trilaciclib in first-line small cell lung cancer patients receiving chemotherapy.”

Click here to read the full press release.

astrazeneca cancer chemotherapy enrollment financial results g1 therapeutics oncology patient patient enrollment patients Genetics Investing